Aug 29, 2017
With a new consultation from the UK’s Department of Health proposing changes to the Statutory Scheme for Pricing of Branded Medicines, what could this mean for negotiation of a successor to the Pharmaceutical Price Regulation Scheme? Leela Barham reports.
Aug 28, 2017
A long list of high priority issues requiring immediate attention on Capitol Hill leaves little time to consider drug access proposals that have limited bipartisan support, writes Jill Wechsler.
Aug 28, 2017
The federal Open Payments program is finally reaching its goal—to halt the adoption of multiple “transparency” initiatives. But will it make a difference, asks Jill Wechsler.
Aug 07, 2017
Jill Wechsler on the Senate's 94-1 vote to approve legislation reauthorizing user fees and a series of program changes to maintain a smoothly functioning FDA product review and approval process.
Aug 07, 2017
Pharmaceutical Executive
A review of the top contenders to land the agency as decision on its relocation draws closer.
Aug 04, 2017
Pharmaceutical Executive
The growing toll requires new assessment of risks, expanded provider education, and more scrutiny of marketed products.
Aug 03, 2017
Pharmaceutical Executive
The agency’s new commissioner unveiled new digital health pilot programs to help navigate regulatory requirements.
Jul 31, 2017
Internal oversight and the tools to remain compliant are critical to companies seeking to avoid corporate integrity agreements or efficiently fulfill existing agreements, writes Gabriela P. Baron.
Jul 24, 2017
Pharmaceutical Executive
Excitement over more new treatments for cancer and rare diseases is offset by cringing over prices.
Jul 21, 2017
The UK's proposed Accelerated Access Review is being dogged by delay and disappointment, writes Leela Barham.
lorem ipsum